GlassScriptPhysician profile
Avraham Miller
NPI 1154749695
$4,894.70
in general payments reported to CMS, 2019-2025
21 companies · $841 in 2025
The $841 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $198 · 2021: $382 · 2022: $726 · 2023: $2,234 · 2024: $22.27 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199 · Travel and Lodging: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.72 |
| Travel and Lodging | $899.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,173.86 | 2023-2025 | Optis, Pressurewire, Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $479.18 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $394.27 | 2019-2024 | Avvigo Guidance System |
| Medtronic, INC. | $309.90 | 2025 | Symplicity G3 |
| Abiomed | $224.09 | 2021-2022 | |
| Biotronik INC. | $188.93 | 2022-2025 | |
| Pfizer INC. | $168.43 | 2021-2022 | |
| Amgen INC. | $125.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $117.76 | 2019 | |
| Kestra Medical Technology Services, INC. | $106.51 | 2023 | Assure Wcd |
| Angiodynamics, INC. | $105.57 | 2023 | Angiovac |
| Recor Medical INC | $97.63 | 2025 | Paradise Ultrasound Renal Denervation System |
| Penumbra, INC. | $96.59 | 2022 | |
| Sanofi-Aventis U.S. LLC | $70.13 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $55.24 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $48.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $47.06 | 2019 | |
| Shockwave Medical, INC | $25.94 | 2022 | |
| Bridgebio Pharma, INC. | $23.66 | 2025 | Attruby |
| Cordis US Corp. | $21.20 | 2022 | |
| Merck Sharp & Dohme LLC | $15.01 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avraham Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.